6',7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice: Effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 3, 1999, Pages 237-244

  Edwards, David J ^b   Fitzsimmons, Michael E ^b   Schuetz, Erin G ^b   Yasuda, Kazuto ^b   Ducharme, Murray P ^b   Warbasse, Lawrence H ^b   Woster, Patrick M ^b   Schuetz, John D ^b   Watkins, Paul ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

6',7' DIHYDROXYBERGAMOTTIN; AMIODARONE; CYCLOSPORIN; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DRUG METABOLIZING ENZYME; FUROCOUMARIN DERIVATIVE; GLYCOPROTEIN P; PETHIDINE; UNCLASSIFIED DRUG; VINBLASTINE; WATER;

ADULT; AREA UNDER THE CURVE; ARTICLE; CELL LEVEL; CELL TRANSPORT; CITRUS FRUIT; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; DUODENUM BIOPSY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FOOD DRUG INTERACTION; FRUIT JUICE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL;

EID: 1442321728     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70102-5     Document Type: Article

References (38)

1. 1. Bailey DG, Spence JD, Munoz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991;337:268-9.
2. 2. Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995;58:20-8.
3. 3. Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 1995;58:127-31.
4. 4. Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarizaon on the electrocardiogram. Clin Pharmacol Ther 1996;59:383-8.
5. 5. Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG. Grapefruit juice-terfenadine single-dose interaction: magnitude, mechanism, and relevance. Clin Pharmacol Ther 1997;61:401-9.
6. 6. Ducharme MP, Provenzano R, Dehoorne-Smith M, Edwards DJ. Trough concentrations of cyclosporine in blood following administration with grapefruit juice. Br J Clin Pharmacol 1993;36:457-9.
7. 7. Yee GC, Stanley DL, Pessa LJ, Dall Costa T, Beltz SE, Ruiz J, et al. Effect of grapefruit juice on blood cyclosporine concentration. Lancet 1995;345:955-6.
8. 8. Proppe DG, Hoch OD, McLean AJ, Visser KE. Influence of chronic ingestion of grapefruit juice on steady-state blood concentrations of cyclosporine A in renal transplant patients with stable graft function. Br J Clin Pharmacol 1995;39:337-8.
9. 9. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995;57:485-91.
10. 10. Lundahl J, Regardh CG, Edgar B, Johnsson G. Effects of grapefruit juice ingestion-pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol 1997;52:139-45.
11. 11. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997;99:2545-53.
12. 12. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450111A4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8.
13. 13. Edwards DJ, Bernier SM. Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice. Life Sci 1996;59:1025-30.
14. 14. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents: decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997;25:1228-33.
15. 15. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon K, Schmiedlin-Ren P, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62:248-60.
16. 1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 1990;11:2275-9.
17. 17. Miniscalco A, Lundahl J, Regardh CG, Edgar B, Eriksson UG. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J Pharmacol Exp Ther 1992;261:1195-9.
18. 18. Bailey DG, Arnold JMO, Munoz C, Spence JD. Grapefruit juice-felodipine interaction: mechanism, predictability and effect of naringin. Clin Pharmacol Ther 1993;53:637-42.
19. 19. Rashid J, McKinstry C, Renwick AG, Dirnhuber M, Waller DG, George CF. Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. Br J Clin Pharmacol 1993;35:460-3.
20. 20. Edwards DJ, Bellevue FH, Woster PM. Identification of 6′,7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 1996;24:1287-90.
21. 21. Fukuda K, Ohta T, Oshima Y, Ohashi N, Yoshikawa M, Yamazoe Y. Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics 1997;7:391-6.
22. 22. He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 1998;11:252-9.
23. 23. Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 1997;25:256-66.
24. 24. Schinkel AH, Wagenaar E, van Deemter L, Mol C, Borst P. Absence of the mdr1a p-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A. J Clin Invest 1995;96:1698-705.
25. 25. Lan LB, Ayesh S, Lyubimov E, Pashinsky I, Stein WD. Kinetic parameters for reversal of the multidrug pump as measured for drug accumulation and cell killing. Cancer Chemother Pharmacol 1996;38:181-90.
26. 26. Liminga G, Nygren P, Larsson R. Microfluorometric evaluation of calcein acetoxymethylester as a probe for P-glycoprotein-mediated resistance: effects of cyclosporin A and its non immunosuppressive analogue SDZ PSC 833. Exp Cell Res 1994;212:291-6.
27. 27. Tiberghien F, Loor F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs 1996;7:568-78.
28. 28. Cai Y, Baer-Dubowska W, Ashwood-Smith MJ, Ceska O, Tachibana S, DiGiovanni J. Mechanism-based inactivation of hepatic ethoxyresorufin O-dealkylation activity by naturally occurring coumarins. Chem Res Toxicol 1996;9: 729-36.
29. 29. Koenigs LL, Peter RM, Thompson SJ, Rettie AE, Trager WF. Mechanism-based inactivation of human liver cytochrome P450 2A6. Drug Metab Dispos 1997;25: 1407-15.
30. 30. Letteron P, Descatoire V, Larrey D, Tinel M, Geneva J, Pessayre D. Inactivation and induction of cytochrome P450 by various psoralen derivatives in rats. J Pharmacol ExpTher 1986;238:685-92.
31. 31. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993;268:6077-80.
32. 32. Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol 1996;118:1841-7.
33. 33. Stein WD. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol Rev 1997;77:545-90.
34. 34. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995;13:129-34.
35. 35. Siegsmund MJ, Cardarelli C, Aksentijevich I, Sugimoto Y, Pastan I, Gottesman MM. Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells. J Urol 1994;151:485-91.
36. 36. Hofsli E, Nissen-Meyer J. Effect of erythromycin and tumour necrosis factor on the drug resistance of multidrug-resistant cells: reversal of drug resistance by erythromycin. Int J Cancer 1989;43:520-5.
37. 37. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996;49:311-8.
38. 38. Shapiro AB, Ling V. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted p-glycoprotein. Biochem Pharmacol 1997;53:587-96.